PRasugrEl Monotherapy Following prImary percUtaneous Coronary Intervention for ST-elevation Myocardial Infarction

Launched by KINDAI UNIVERSITY · Feb 1, 2023

Keywords

ClinConnect Summary

This clinical trial is studying the safety of a medication called prasugrel when used alone, without aspirin, in people who have had a heart attack known as STEMI. The trial compares this single medication approach to the standard treatment, which includes both aspirin and prasugrel for 12 months after a special procedure called primary percutaneous coronary intervention (PCI) that places a stent in the heart. The goal is to see if using prasugrel by itself is just as safe for patients while they recover.

To be eligible for this trial, participants need to be adults aged 65 and older who are scheduled for the heart procedure using a specific type of stent (called the SYNERGY™ stent). They must also be able to take both aspirin and prasugrel for a year after the procedure. However, people who are on other blood-thinning medications, those under 18, or those who have a life expectancy of less than a year cannot join the study. If you participate, you can expect regular check-ups to monitor your health and how well the medication works for you. This trial is currently looking for new participants, so if you qualify, you could play a key role in helping us understand better treatment options for heart attack recovery.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients scheduled for primary PCI with everolimus-eluting stent (PtCr-EES, SYNERGYTM)
• • STEMI patients
• • Patients who can continue dual antiplatelet therapy with aspirin and a P2Y12 inhibitor for 12 months
• Exclusion Criteria:
• • Patients taking anticoagulants
• • Patients under 18 years old
• • Patients with less than 1 year prognosis
• • Patients participating in other intervention studies